ulodesine
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2009 (NCT00985127)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Purine nucleoside phosphorylaseINHIBITOR
PNP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]cnc2c(CN3C[C@H](CO)[C@@H](O)C3)c[nH]c12- Mol. weight
- 264.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL269864 ↗
Also known as
- bcx-3408
- bcx-3408
- bcx4208
- bcx4208
- bcx4208
- r-3421
- r-3421
- ulodesine
- ulodesine
- ulodesine
- ulodesine
- ulodesine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01407874 | Phase 2 | Sep 1, 2011 | BioCryst |
| NCT01265264 | Phase 2 | Dec 1, 2010 | BioCryst |
| NCT01129648 | Phase 2 | May 1, 2010 | BioCryst |
| NCT00985127 | Phase 2 | Sep 1, 2009 | BioCryst |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioCryst | For profit | 4 | 4 | 1 | 2009 |
1 organizations
Page 1 / 1